Related Experiment Video
Updated: May 29, 2026
11:13
Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
Leptin and breast cancer: an overview
1Division of Medical Oncology, Selcuk University Meram Medical Faculty, Konya, Turkey.
Medical Oncology (Northwood, London, England)
|August 31, 2011
Summary
Leptin, a key obesity hormone, is overexpressed in breast cancer, correlating with tumor progression and poor survival. Targeting the leptin system offers a promising new therapeutic strategy for breast cancer treatment.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Leptin is a critical mediator of obesity.
- Leptin and its receptor are frequently overexpressed in breast cancer, particularly in high-grade tumors.
- This overexpression is associated with disease progression and reduced patient survival.
Purpose of the Study:
- To review the current understanding of the relationship between leptin and breast cancer.
- To highlight leptin's role in breast cancer development and progression.
- To discuss the leptin system as a potential therapeutic target.
Main Methods:
- Literature review of existing studies on leptin and breast cancer.
- Analysis of the molecular mechanisms linking leptin to cancer biology.
- Synthesis of data regarding clinical associations and therapeutic implications.
Main Results:
- Leptin promotes endothelial cell proliferation and angiogenesis, crucial processes in tumor growth.
- The leptin system's involvement in breast cancer is complex, potentially interacting with factors like insulin and HER2.
- Elevated leptin levels are linked to aggressive tumor characteristics and poorer outcomes.
Conclusions:
- The leptin system represents a significant factor in breast cancer pathogenesis.
- Leptin's pro-angiogenic and proliferative effects underscore its role in tumor progression.
- Targeting the leptin pathway presents a promising avenue for novel breast cancer therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
03:18Non-LTR Retrotransposons
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...